Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035

1 INTRODUCTION 32 1.1 STUDY OBJECTIVES 32 1.2 MARKET DEFINITION 32 1.3 MARKET SCOPE 33 1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 33 1.3.2 INCLUSIONS & EXCLUSIONS 34 1.3.3 YEARS CONSIDERED 34 1.3.4 CURRENCY CONSIDERED 35 1.4 STAKEHOLDERS 35 2 EXECUTIVE SUMMARY 36 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 36 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 37 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 38 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 39 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 40 3 PREMIUM INSIGHTS 42 3.1 NEXT-GENERATION DRUG CONJUGATES MARKET OVERVIEW 42 3.2 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND & REGION 43 3.3 NEXT-GENERATION DRUG CONJUGATES MARKET: GEOGRAPHIC SNAPSHOT 44 4 MARKET OVERVIEW 45 4.1 INTRODUCTION 45 4.2 MARKET DYNAMICS 45 4.2.1 DRIVERS 46 4.2.1.1 Increasing clinical success and regulatory approvals of antibody-drug conjugates 46 4.2.1.2 Technological advancements in linker chemistry and payload development 47 4.2.2 RESTRAINTS 47 4.2.2.1 High development and manufacturing costs associated with complex biologics 47 4.2.3 OPPORTUNITIES 48 4.2.3.1 Expansion of drug conjugates into non-oncology therapeutic areas 48 4.2.3.2 Increasing developments of novel conjugate platforms 48 4.2.4 CHALLENGES 48 4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses 48   4.3 UNMET NEEDS AND WHITE SPACES 49 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 49 4.4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE 50 4.4.2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE 51 4.4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE 51 4.4.4 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE 52 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52 5 INDUSTRY TRENDS 53 5.1 PORTER’S FIVE FORCES ANALYSIS 53 5.1.1 THREAT OF NEW ENTRANTS 54 5.1.2 THREAT OF SUBSTITUTES 54 5.1.3 BARGAINING POWER OF BUYERS 54 5.1.4 BARGAINING POWER OF SUPPLIERS 54 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54 5.2 MACROECONOMIC OUTLOOK 55 5.2.1 INTRODUCTION 55 5.2.2 GDP TRENDS AND FORECAST 55 5.2.3 TRENDS IN GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET 56 5.3 VALUE CHAIN ANALYSIS 56 5.4 ECOSYSTEM ANALYSIS 58 5.5 PRICING ANALYSIS 60 5.5.1 INDICATIVE SELLING PRICE, BY KEY PLAYER, 2025 (USD) 60 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD) 61 5.5.3 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD) 62 5.6 KEY CONFERENCES & EVENTS 63 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 63 5.8 INVESTMENT & FUNDING ACTIVITY 64 5.9 IMPACT OF US TARIFFS—NEXT-GENERATION DRUG CONJUGATES MARKET 65 5.9.1 INTRODUCTION 65 5.9.2 KEY TARIFF RATES 66 5.9.3 PRICE IMPACT ANALYSIS 67 5.9.4 IMPACT ON COUNTRIES/REGIONS 67 5.9.4.1 North America 67 5.9.4.2 Europe 68 5.9.4.3 Asia Pacific 68 5.9.5 IMPACT ON END-USE INDUSTRIES 69 5.9.5.1 Hospitals 69 5.9.5.2 Specialty clinics and cancer centers 69 5.9.5.3 Other specialty care settings 69 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS 70 6.1 TECHNOLOGY ANALYSIS 70 6.1.1 KEY TECHNOLOGIES 70 6.1.1.1 New-generation payload chemistries 70 6.1.1.2 Radioligand/theranostic conjugate engineering 70 6.1.2 ADJACENT TECHNOLOGIES 71 6.1.2.1 Protein engineering/antibody engineering 71 6.1.3 COMPLEMENTARY TECHNOLOGIES 71 6.1.3.1 Diagnostic imaging/theranostics workflows 71 6.2 TECHNOLOGY/PRODUCT ROADMAP 71 6.3 FUTURE APPLICATIONS 72 6.4 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET 72 6.4.1 TOP USE CASES AND MARKET POTENTIAL 73 6.4.2 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET 74 6.4.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 74 6.4.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEXT-GENERATION DRUG CONJUGATES MARKET 75 6.5 PIPELINE ANALYSIS 75 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 77 7.1 REGIONAL REGULATIONS AND COMPLIANCE 77 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT 80 7.1.2.1 Reimbursement scenario 81 7.1.3 INDUSTRY STANDARDS 83 7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 84 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 85 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 86 8.1 DECISION-MAKING PROCESS 86 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 86 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 86 8.2.2 KEY BUYING CRITERIA, BY END USER 87 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 88 8.4 UNMET NEEDS FROM END USERS 89 8.5 MARKET PROFITABILITY 89   9 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT 90 9.1 INTRODUCTION 91 9.2 ENHERTU 91 9.2.1 BROAD CLINICAL ADOPTION AND REGULATORY EXPANSION OF TARGETED ADC THERAPIES DRIVE MARKET GROWTH 91 9.3 PLUVICTO 94 9.3.1 EXPANDING USE OF TARGETED RADIOLIGAND THERAPY IN PROSTATE CANCER TO DRIVE MARKET GROWTH 94 9.4 AMVUTTRA 97 9.4.1 ADVANCING RNAI THERAPEUTICS THROUGH DURABLE GENE SILENCING AND EXPANDED INDICATION REACH 97 9.5 TRODELVY 100 9.5.1 RISING GOVERNMENT APPROVALS FOR BREAST CANCER TREATMENTS TO DRIVE MARKET GROWTH 100 9.6 SACITUZUMAB TIRUMOTECAN 103 9.6.1 ADVANCING NEXT-GENERATION ADC PAYLOAD INNOVATION IN NDC MARKET 103 9.7 PATRITUMAB DERUXTECAN 106 9.7.1 ADVANCEMENTS IN HER3-DIRECTED ANTIBODY-DRUG CONJUGATES TO AID GROWTH 106 9.8 225AC-PSMA-617 109 9.8.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO SUPPORT MARKET GROWTH 109 9.9 OTHER COMMERCIALIZED PRODUCTS 112 9.10 OTHER PIPELINE PRODUCTS 115 10 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE 119 10.1 INTRODUCTION 120 10.2 ANTIBODY–SMALL MOLECULE CONJUGATES 120 10.2.1 ENHANCED CLINICAL UTILITY AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET 120 10.3 PEPTIDE–RADIONUCLIDE CONJUGATES 123 10.3.1 INNOVATIONS IN PRECISION ONCOLOGY APPLICATIONS AND TECHNOLOGICAL ADVANCEMENTS SUPPORT GROWTH 123 10.4 LIGAND–OLIGONUCLEOTIDE CONJUGATES 126 10.4.1 ENHANCED DELIVERY AND TISSUE TARGETING CAPABILITIES OF LIGAND–OLIGONUCLEOTIDE CONJUGATES DRIVE GROWTH 126 10.5 OTHER DRUG CONJUGATES 129 11 NEXT-GENERATION DRUG MARKET, BY TARGET LIGAND 133 11.1 INTRODUCTION 134 11.2 ANTIBODIES 134 11.2.1 ADVANCEMENTS IN ANTIBODY ENGINEERING AND EXPANDING TARGET DIVERSITY DRIVE GROWTH 134   11.3 AMINO SUGARS 137 11.3.1 GROWING ADOPTION OF GALNAC-BASED LIVER-TARGETING PLATFORMS DRIVES EXPANSION 137 11.4 SMALL MOLECULES 140 11.4.1 EXPANDING USE OF SMALL-MOLECULE TARGETING LIGANDS IS BROADENING THE NEXT-GENERATION DRUG CONJUGATES MARKET 140 11.5 PEPTIDES 143 11.5.1 EXPANDING CLINICAL PIPELINES AND TUMOR-TARGETING INNOVATIONS PROPEL GROWTH 143 12 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE 147 12.1 INTRODUCTION 148 12.2 SMALL-MOLECULE PAYLOADS 148 12.2.1 RISING ADOPTION OF HIGHLY POTENT, NEXT-GENERATION PAYLOADS AND ADVANCED LINKER TECHNOLOGIES IS ACCELERATING GROWTH 148 12.3 OLIGONUCLEOTIDE PAYLOADS 151 12.3.1 RISING ADOPTION OF RNA-BASED GENE-SILENCING THERAPIES AND LONG-ACTING CONJUGATE PLATFORMS TO DRIVE MARKET 151 12.4 RADIONUCLIDE PAYLOADS 154 12.4.1 EXPANDING RADIOLIGAND THERAPY ADOPTION AND ADVANCEMENTS IN ISOTOPE TECHNOLOGIES SUPPORT MARKET GROWTH 154 13 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION 158 13.1 INTRODUCTION 159 13.2 BREAST CANCER 159 13.2.1 RISING INCIDENCE AND INCREASING ADOPTION OF TARGETED ADC THERAPIES TO DRIVE MARKET 159 13.3 HATTR WITH POLYNEUROPATHY 162 13.3.1 ADVANCEMENTS IN RNA-BASED GENE-SILENCING THERAPIES AND INCREASING DIAGNOSIS RATES ARE DRIVING GROWTH 162 13.4 PROSTATE CANCER 165 13.4.1 EXPANDING ADOPTION OF PSMA-TARGETED RADIOLIGAND THERAPIES IS DRIVING GROWTH 165 13.5 PRIMARY HYPERLIPIDEMIA 168 13.5.1 INCREASING ADOPTION OF LONG-ACTING RNA-BASED THERAPIES DRIVES MARKET GROWTH 168 13.6 OTHER INDICATIONS 171 14 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION 175 14.1 INTRODUCTION 176 14.2 NORTH AMERICA 176 14.2.1 US 180 14.2.1.1 FDA approvals, expanding clinical pipelines, and strategic collaborations drive market 180   14.2.2 CANADA 182 14.2.2.1 Increasing access to innovative NDC therapies drives growth 182 14.3 EUROPE 185 14.3.1 GERMANY 188 14.3.1.1 Access to innovative therapies and strong radioligand infrastructure are driving growth 188 14.3.2 UK 190 14.3.2.1 Rising demand for precision oncology and advanced conjugate technologies drives market expansion 190 14.3.3 FRANCE 193 14.3.3.1 Biopharma presence and global innovation in targeted conjugates support market growth 193 14.3.4 ITALY 195 14.3.4.1 Expanding clinical research to accelerate market growth 195 14.3.5 SPAIN 198 14.3.5.1 Increased focus on research for NDC development to propel market growth 198 14.3.6 REST OF EUROPE 200 14.4 ASIA PACIFIC 203 14.4.1 CHINA 206 14.4.1.1 Strong domestic innovation and expanding oncology demand drive NDC market growth 206 14.4.2 JAPAN 209 14.4.2.1 Growing drug approvals and pharma biotech research initiatives support market growth 209 14.4.3 INDIA 211 14.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies support growth 211 14.4.4 SOUTH KOREA 214 14.4.4.1 Key drug approvals relevant to NDC market to aid growth in South Korea 214 14.4.5 AUSTRALIA 216 14.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth 216 14.4.6 REST OF ASIA PACIFIC 219 14.5 LATIN AMERICA 221 14.5.1 BRAZIL 225 14.5.1.1 Expanding clinical trials and rising demand for targeted oncology therapies drive market growth 225 14.5.2 MEXICO 227 14.5.2.1 Gradual increase in pharmaceutical R&D to support market growth 227 14.5.3 REST OF LATIN AMERICA 230   14.6 MIDDLE EAST 232 14.6.1 GCC COUNTRIES 235 14.6.1.1 Integration of genomics, biomarker-driven diagnostics, and personalized treatment to propel market 235 14.6.2 REST OF MIDDLE EAST 238 14.7 AFRICA 240 14.7.1 RESEARCH COLLABORATIONS AND INFRASTRUCTURAL DEVELOPMENT TO DRIVE MARKET 240 15 COMPETITIVE LANDSCAPE 243 15.1 OVERVIEW 243 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 243 15.3 REVENUE ANALYSIS, 2021–2025 244 15.4 MARKET SHARE ANALYSIS 245 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 248 15.5.1 STARS 248 15.5.2 EMERGING LEADERS 248 15.5.3 PERVASIVE PLAYERS 248 15.5.4 PARTICIPANTS 248 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 250 15.5.5.1 Company footprint 250 15.5.5.2 Region footprint 251 15.5.5.3 Type footprint 252 15.5.5.4 Indication footprint 253 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 254 15.6.1 PROGRESSIVE COMPANIES 254 15.6.2 RESPONSIVE COMPANIES 254 15.6.3 DYNAMIC COMPANIES 254 15.6.4 STARTING BLOCKS 254 15.6.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 256 15.6.5.1 Detailed list of key startups/SMEs 256 15.7 COMPANY VALUATION AND FINANCIAL METRICS 258 15.8 BRAND COMPARISON 259 15.9 COMPETITIVE SCENARIO 260 15.9.1 PRODUCT APPROVALS 260 15.9.2 DEALS 261 15.9.3 EXPANSIONS 262 16 COMPANY PROFILES 264 16.1 KEY PLAYERS 264 16.1.1 ASTRAZENECA 264 16.1.1.1 Business overview 264 16.1.1.2 Products offered 265 16.1.1.3 Recent developments 266 16.1.1.3.1 Product approvals 266 16.1.1.3.2 Deals 266 16.1.1.3.3 Expansions 267 16.1.1.4 MnM view 267 16.1.1.4.1 Key strengths/Right to win 267 16.1.1.4.2 Strategic choices made 267 16.1.1.4.3 Weaknesses and competitive threats 267 16.1.2 DAIICHI SANKYO COMPANY, LIMITED 268 16.1.2.1 Business overview 268 16.1.2.2 Products offered 269 16.1.2.3 Products in pipeline 269 16.1.2.4 Recent developments 270 16.1.2.4.1 Product approvals 270 16.1.2.4.2 Expansions 270 16.1.2.5 MnM view 270 16.1.2.5.1 Key strengths/Right to win 270 16.1.2.5.2 Strategic choices made 271 16.1.2.5.3 Weaknesses and competitive threats 271 16.1.3 NOVARTIS AG 272 16.1.3.1 Business overview 272 16.1.3.2 Products offered 273 16.1.3.3 Recent developments 274 16.1.3.3.1 Product approvals 274 16.1.3.3.2 Deals 274 16.1.3.3.3 Expansions 275 16.1.3.4 MnM view 276 16.1.3.4.1 Key strengths/Right to win 276 16.1.3.4.2 Strategic choices made 276 16.1.3.4.3 Weaknesses and competitive threats 276 16.1.4 ALNYLAM PHARMACEUTICALS, INC 277 16.1.4.1 Business overview 277 16.1.4.2 Products offered 279 16.1.4.3 Recent developments 279 16.1.4.3.1 Product approvals 279 16.1.4.3.2 Deals 280 16.1.4.3.3 Expansions 280 16.1.4.4 MnM view 281 16.1.4.4.1 Key strengths/Right to win 281 16.1.4.4.2 Strategic choices made 281 16.1.4.4.3 Weaknesses and competitive threats 281   16.1.5 GILEAD SCIENCES, INC. 282 16.1.5.1 Business overview 282 16.1.5.2 Products offered 284 16.1.5.3 Recent developments 284 16.1.5.3.1 Deals 284 16.1.5.3.2 Expansions 285 16.1.5.4 MnM view 285 16.1.5.4.1 Key strengths/Right to win 285 16.1.5.4.2 Strategic choices made 285 16.1.5.4.3 Weaknesses and competitive threats 285 16.1.6 IONIS PHARMACEUTICALS, INC. 286 16.1.6.1 Business overview 286 16.1.6.2 Products offered 287 16.1.6.3 Products in pipeline 287 16.1.6.4 Recent developments 288 16.1.6.4.1 Product approvals 288 16.1.6.4.2 Deals 288 16.1.7 RAKUTEN GROUP, INC. 289 16.1.7.1 Business overview 289 16.1.7.2 Products in pipeline 290 16.1.7.3 Recent developments 291 16.1.7.3.1 Deals 291 16.1.8 NOVO NORDISK 292 16.1.8.1 Business overview 292 16.1.8.2 Products offered 293 16.1.8.3 Recent developments 294 16.1.8.3.1 Product approvals 294 16.1.8.3.2 Deals 294 16.1.9 ADC THERAPEUTICS SA 295 16.1.9.1 Business overview 295 16.1.9.2 Products offered 296 16.1.9.3 Products in pipeline 296 16.1.10 SANOFI 297 16.1.10.1 Business overview 297 16.1.10.2 Products offered 298 16.1.10.3 Products in pipeline 298 16.1.10.4 Recent developments 299 16.1.10.4.1 Deals 299 16.1.11 ARROWHEAD PHARMACEUTICALS 300 16.1.11.1 Business overview 300 16.1.11.2 Products offered 301 16.1.11.3 Recent developments 301 16.1.11.3.1 Product approvals 301 16.1.12 ABBVIE INC. 302 16.1.12.1 Business overview 302 16.1.12.2 Products in pipeline 302 16.1.13 REGENERON PHARMACEUTICALS INC. 303 16.1.13.1 Business overview 303 16.1.13.2 Products in pipeline 303 16.2 OTHER PLAYERS 304 16.2.1 BICYCLE THERAPEUTICS 304 16.2.2 AVIDITY BIOSCIENCES 305 16.2.3 SILENCE THERAPEUTICS 305 16.2.4 MEDILINK THERAPEUTICS 306 16.2.5 SYSTIMMUNE, INC. 306 16.2.6 ACTINIUM PHARMACEUTICALS 307 16.2.7 ALPHAMAB ONCOLOGY 307 16.2.8 FUSION PHARMA 308 16.2.9 ORANO GROUP 308 16.2.10 PEPGEN INC 309 16.2.11 TUBULIS GMBH 309 16.2.12 CLARITY PHARMACEUTICALS 310 17 RESEARCH METHODOLOGY 311 17.1 RESEARCH DATA 311 17.1.1 SECONDARY DATA 312 17.1.2 PRIMARY DATA 313 17.2 MARKET ESTIMATION METHODOLOGY 314 17.2.1 MARKET SIZE ESTIMATION 314 17.2.2 INSIGHTS OF PRIMARY EXPERTS 316 17.2.3 TOP-DOWN APPROACH 317 17.3 MARKET GROWTH RATE PROJECTIONS 318 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 319 17.5 RESEARCH ASSUMPTIONS 320 17.6 RESEARCH LIMITATIONS 321 17.7 RISK ANALYSIS 321 18 APPENDIX 322 18.1 DISCUSSION GUIDE 322 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 326 18.3 CUSTOMIZATION OPTIONS 328 18.4 RELATED REPORTS 329 18.5 AUTHOR DETAILS 330

TABLE 1 NEXT-GENERATION DRUG CONJUGATES MARKET: IMPACT ANALYSIS 46 TABLE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION) 50 TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 51 TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 51 TABLE 5 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE, 2022–2029 (USD MILLION) 52 TABLE 6 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER’S FIVE FORCES ANALYSIS 54 TABLE 7 NEXT-GENERATION DRUG CONJUGATES MARKET: ROLE IN ECOSYSTEM 59 TABLE 8 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD) 60 TABLE 9 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD) 61 TABLE 10 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD) 62 TABLE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY CONFERENCES & EVENTS, 2026–2027 63 TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 66 TABLE 13 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET 74 TABLE 14 CLIENT’S READINESS TO ADOPT GENERATIVE AI 75 TABLE 15 KEY PIPELINE PRODUCTS IN NEXT-GENERATION DRUG CONJUGATES MARKET (AS OF MARCH 2026) 76 TABLE 16 EXAMPLES OF US REGULATORY PATHWAY, BY TYPE OF DRUG CONJUGATE 77 TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 21 REIMBURSEMENT STATUS AND TYPE, BY COUNTRY 81 TABLE 22 COUNTRY-WISE REGULATORY SCENARIO FOR NEXT-GENERATION DRUG CONJUGATE MANUFACTURERS 83 TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 87 TABLE 24 KEY BUYING CRITERIA, BY END USER 87 TABLE 25 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 91 TABLE 26 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION) 92 TABLE 27 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION) 92 TABLE 28 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION) 93 TABLE 29 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION) 93 TABLE 30 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION) 94 TABLE 31 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION) 94 TABLE 32 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION) 95 TABLE 33 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION) 95 TABLE 34 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION) 96 TABLE 35 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION) 96 TABLE 36 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO , BY COUNTRY, 2024–2035 (USD MILLION) 97 TABLE 37 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION) 97 TABLE 38 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION) 98 TABLE 39 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION) 98 TABLE 40 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION) 99 TABLE 41 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION) 99 TABLE 42 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION) 100 TABLE 43 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION) 100 TABLE 44 NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION) 101 TABLE 45 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION) 101 TABLE 46 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION) 102 TABLE 47 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION) 102 TABLE 48 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION) 103 TABLE 49 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION) 103 TABLE 50 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION) 104 TABLE 51 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 104 TABLE 52 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 105 TABLE 53 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 105 TABLE 54 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 106 TABLE 55 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION) 106 TABLE 56 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION) 107 TABLE 57 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 107 TABLE 58 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 108 TABLE 59 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 108 TABLE 60 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 109 TABLE 61 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION) 109 TABLE 62 NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION) 110 TABLE 63 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 110 TABLE 64 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 111 TABLE 65 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 111 TABLE 66 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 112 TABLE 67 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION) 112 TABLE 68 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 113 TABLE 69 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 113 TABLE 70 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 114 TABLE 71 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 114 TABLE 72 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 115 TABLE 73 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 115 TABLE 74 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 116 TABLE 75 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 116 TABLE 76 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 117 TABLE 77 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 117 TABLE 78 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 118 TABLE 79 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 118 TABLE 80 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 120 TABLE 81 ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 121 TABLE 82 NORTH AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 121 TABLE 83 EUROPE: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 122 TABLE 84 ASIA PACIFIC: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 122 TABLE 85 LATIN AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 123 TABLE 86 MIDDLE EAST: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 123 TABLE 87 PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 124 TABLE 88 NORTH AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 124 TABLE 89 EUROPE: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 125 TABLE 90 ASIA PACIFIC: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 125 TABLE 91 LATIN AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 126 TABLE 92 MIDDLE EAST: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 126 TABLE 93 LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 127 TABLE 94 NORTH AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 127 TABLE 95 EUROPE: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 128 TABLE 96 ASIA PACIFIC: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 128 TABLE 97 LATIN AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 129 TABLE 98 MIDDLE EAST: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 129 TABLE 99 OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 130 TABLE 100 NORTH AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 130 TABLE 101 EUROPE: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 131 TABLE 102 ASIA PACIFIC: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 131 TABLE 103 LATIN AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 132 TABLE 104 MIDDLE EAST: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 132 TABLE 105 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 134 TABLE 106 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION) 135 TABLE 107 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 135 TABLE 108 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 136 TABLE 109 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 136 TABLE 110 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 137 TABLE 111 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION) 137 TABLE 112 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION) 138 TABLE 113 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 138 TABLE 114 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 139 TABLE 115 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 139 TABLE 116 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 140 TABLE 117 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION) 140 TABLE 118 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION) 141 TABLE 119 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 141 TABLE 120 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 142 TABLE 121 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 142 TABLE 122 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 143 TABLE 123 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION) 143 TABLE 124 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION) 144 TABLE 125 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION) 144 TABLE 126 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION) 145 TABLE 127 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION) 145 TABLE 128 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION) 146 TABLE 129 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION) 146 TABLE 130 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 148 TABLE 131 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 149 TABLE 132 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 149 TABLE 133 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 150 TABLE 134 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 150 TABLE 135 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 151 TABLE 136 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 151 TABLE 137 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 152 TABLE 138 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 152 TABLE 139 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 153 TABLE 140 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 153 TABLE 141 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 154 TABLE 142 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 154 TABLE 143 NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 155 TABLE 144 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 155 TABLE 145 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 156 TABLE 146 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 156 TABLE 147 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 157 TABLE 148 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 157 TABLE 149 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 159 TABLE 150 NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION) 160 TABLE 151 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 160 TABLE 152 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 161 TABLE 153 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 161 TABLE 154 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 162 TABLE 155 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION) 162 TABLE 156 NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION) 163 TABLE 157 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 163 TABLE 158 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 164 TABLE 159 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 164 TABLE 160 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 165 TABLE 161 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION) 165 TABLE 162 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION) 166 TABLE 163 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 166 TABLE 164 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 167 TABLE 165 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 167 TABLE 166 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 168 TABLE 167 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION) 168 TABLE 168 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION) 169 TABLE 169 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 169 TABLE 170 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 170 TABLE 171 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 170 TABLE 172 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 171 TABLE 173 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION) 171 TABLE 174 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION) 172 TABLE 175 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 172 TABLE 176 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 173 TABLE 177 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 173 TABLE 178 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 174 TABLE 179 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION) 174 TABLE 180 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 176 TABLE 181 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 177 TABLE 182 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 178 TABLE 183 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 178 TABLE 184 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 179 TABLE 185 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 179 TABLE 186 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 179 TABLE 187 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 180 TABLE 188 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 181 TABLE 189 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 181 TABLE 190 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 182 TABLE 191 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 182 TABLE 192 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 183 TABLE 193 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 183 TABLE 194 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 184 TABLE 195 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 184 TABLE 196 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 184 TABLE 197 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 185 TABLE 198 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 186 TABLE 199 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 186 TABLE 200 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 187 TABLE 201 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 187 TABLE 202 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 187 TABLE 203 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 188 TABLE 204 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 189 TABLE 205 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 189 TABLE 206 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 190 TABLE 207 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 190 TABLE 208 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 191 TABLE 209 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 191 TABLE 210 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 192 TABLE 211 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 192 TABLE 212 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 192 TABLE 213 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 193 TABLE 214 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 194 TABLE 215 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 194 TABLE 216 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 195 TABLE 217 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 195 TABLE 218 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 196 TABLE 219 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 196 TABLE 220 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 197 TABLE 221 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 197 TABLE 222 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 197 TABLE 223 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 198 TABLE 224 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 199 TABLE 225 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 199 TABLE 226 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 200 TABLE 227 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 200 TABLE 228 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 201 TABLE 229 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 201 TABLE 230 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 202 TABLE 231 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 202 TABLE 232 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 202 TABLE 233 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 204 TABLE 234 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 204 TABLE 235 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 205 TABLE 236 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 205 TABLE 237 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 206 TABLE 238 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 206 TABLE 239 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 207 TABLE 240 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 207 TABLE 241 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 208 TABLE 242 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 208 TABLE 243 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 208 TABLE 244 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 209 TABLE 245 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 210 TABLE 246 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 210 TABLE 247 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 211 TABLE 248 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 211 TABLE 249 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 212 TABLE 250 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 212 TABLE 251 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 213 TABLE 252 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 213 TABLE 253 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 213 TABLE 254 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 214 TABLE 255 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 215 TABLE 256 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 215 TABLE 257 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 216 TABLE 258 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 216 TABLE 259 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 217 TABLE 260 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 217 TABLE 261 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 218 TABLE 262 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 218 TABLE 263 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 218 TABLE 264 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 219 TABLE 265 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 220 TABLE 266 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 220 TABLE 267 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 221 TABLE 268 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 221 TABLE 269 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 222 TABLE 270 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 222 TABLE 271 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 223 TABLE 272 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 223 TABLE 273 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 224 TABLE 274 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 224 TABLE 275 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 225 TABLE 276 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 226 TABLE 277 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 226 TABLE 278 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 227 TABLE 279 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 227 TABLE 280 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 228 TABLE 281 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 228 TABLE 282 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 229 TABLE 283 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 229 TABLE 284 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 229 TABLE 285 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 230 TABLE 286 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 231 TABLE 287 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 231 TABLE 288 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 232 TABLE 289 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 232 TABLE 290 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 233 TABLE 291 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 233 TABLE 292 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 234 TABLE 293 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 234 TABLE 294 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 235 TABLE 295 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 235 TABLE 296 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 236 TABLE 297 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 236 TABLE 298 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 237 TABLE 299 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 237 TABLE 300 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 237 TABLE 301 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 238 TABLE 302 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 239 TABLE 303 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 239 TABLE 304 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 239 TABLE 305 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 240 TABLE 306 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 241 TABLE 307 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 241 TABLE 308 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 242 TABLE 309 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 242 TABLE 310 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 242 TABLE 311 STRATEGIES ADOPTED BY KEY PLAYERS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2023−2026 243 TABLE 312 NEXT-GENERATION DRUG CONJUGATES MARKET: DEGREE OF COMPETITION 246 TABLE 313 NEXT-GENERATION DRUG CONJUGATES MARKET: REGION FOOTPRINT 251 TABLE 314 NEXT-GENERATION DRUG CONJUGATES MARKET: TYPE FOOTPRINT 252 TABLE 315 NEXT-GENERATION DRUG CONJUGATES MARKET: INDICATION FOOTPRINT 253 TABLE 316 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY STARTUPS/SMES 256 TABLE 317 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 257 TABLE 318 NEXT-GENERATION DRUG CONJUGATES MARKET: PRODUCT APPROVALS, JANUARY 2023 TO MARCH 2026 260 TABLE 319 NEXT-GENERATION DRUG CONJUGATES MARKET: DEALS, JANUARY 2023 TO MARCH 2026 261 TABLE 320 NEXT-GENERATION DRUG CONJUGATES MARKET: EXPANSIONS, JANUARY 2023 TO MARCH 2026 262 TABLE 321 ASTRAZENECA: COMPANY OVERVIEW 264 TABLE 322 ASTRAZENECA: PRODUCTS OFFERED 265 TABLE 323 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2023– MARCH 2026 266 TABLE 324 ASTRAZENECA: DEALS, JANUARY 2023–MARCH 2026 266 TABLE 325 ASTRAZENECA: EXPANSIONS, JANUARY 2023–MARCH 2026 267 TABLE 326 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 268 TABLE 327 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 269 TABLE 328 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS IN PIPELINE 269 TABLE 329 DAIICHI SANKYO COMPANY, LIMITED: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 270 TABLE 330 DAIICHI SANKYO COMPANY, LIMITED: EXPANSIONS, JANUARY 2023–MARCH 2026 270 TABLE 331 NOVARTIS AG: COMPANY OVERVIEW 272 TABLE 332 NOVARTIS AG: PRODUCTS OFFERED 273 TABLE 333 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 274 TABLE 334 NOVARTIS AG: DEALS, JANUARY 2023–MARCH 2026 274 TABLE 335 NOVARTIS AG: EXPANSIONS, JANUARY 2023–MARCH 2026 275 TABLE 336 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 277 TABLE 337 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED 279 TABLE 338 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 279 TABLE 339 ALNYLAM PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–MARCH 2026 280 TABLE 340 ALNYLAM PHARMACEUTICALS INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 280 TABLE 341 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 282 TABLE 342 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 284 TABLE 343 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023–MARCH 2026 284 TABLE 344 GILEAD SCIENCES, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 285 TABLE 345 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 286 TABLE 346 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED 287 TABLE 347 IONIS PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE 287 TABLE 348 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 288 TABLE 349 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–MARCH 2026 288 TABLE 350 RAKUTEN GROUP, INC.: COMPANY OVERVIEW 289 TABLE 351 RAKUTEN GROUP, INC.: PRODUCTS IN PIPELINE 290 TABLE 352 RAKUTEN GROUP, INC.: DEALS, JANUARY 2023–MARCH 2026 291 TABLE 353 NOVO NORDISK: COMPANY OVERVIEW 292 TABLE 354 NOVO NORDISK: PRODUCTS OFFERED 293 TABLE 355 NOVO NORDISK: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 294 TABLE 356 NOVO NORDISK: DEALS, JANUARY 2023–MARCH 2026 294 TABLE 357 ADC THERAPEUTICS SA: COMPANY OVERVIEW 295 TABLE 358 ADC THERAPEUTICS SA: PRODUCTS OFFERED 296 TABLE 359 ADC THERAPEUTICS SA: PRODUCTS IN PIPELINE 296 TABLE 360 SANOFI: COMPANY OVERVIEW 297 TABLE 361 SANOFI: PRODUCTS OFFERED 298 TABLE 362 SANOFI: PRODUCTS IN PIPELINE 298 TABLE 363 SANOFI: DEALS, JANUARY 2023–MARCH 2026 299 TABLE 364 ARROWHEAD PHARMACEUTICALS: COMPANY OVERVIEW 300 TABLE 365 ARROWHEAD PHARMACEUTICALS: PIPELINE PRODUCTS 301 TABLE 366 ARROWHEAD PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 301 TABLE 367 ABBVIE INC.: COMPANY OVERVIEW 302 TABLE 368 ABBVIE INC.: PRODUCTS IN PIPELINE 302 TABLE 369 REGENERON PHARMACEUTICALS: COMPANY OVERVIEW 303 TABLE 370 REGENERON PHARMACEUTICALS INC.: PRODUCTS IN PIPELINE 303 TABLE 371 BICYCLE THERAPEUTICS: COMPANY OVERVIEW 304 TABLE 372 AVIDITY BIOSCIENCES: COMPANY OVERVIEW 305 TABLE 373 SILENCE THERAPEUTICS: COMPANY OVERVIEW 305 TABLE 374 MEDILINK THERAPEUTICS: COMPANY OVERVIEW 306 TABLE 375 SYSTIMMUNE, INC.: COMPANY OVERVIEW 306 TABLE 376 ACTINIUM PHARMACEUTICALS: COMPANY OVERVIEW 307 TABLE 377 ALPHAMAB ONCOLOGY: COMPANY OVERVIEW 307 TABLE 378 FUSION PHARMA: COMPANY OVERVIEW 308 TABLE 379 ORANO GROUP: COMPANY OVERVIEW 308 TABLE 380 PEPGEN INC.: COMPANY OVERVIEW 309 TABLE 381 TUBULIS GMBH: COMPANY OVERVIEW 309 TABLE 382 CLARITY PHARMACEUTICALS: COMPANY OVERVIEW 310 TABLE 383 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 319 FIGURE 1 MARKET SCENARIO 36 FIGURE 2 GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET, 2024–2035 37 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2023–2026 37 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF NEXT-GENERATION DRUG CONJUGATES MARKET 38 FIGURE 5 HIGH-GROWTH SEGMENTS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2026–2035 39 FIGURE 6 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 40 FIGURE 7 TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND PAYLOAD DEVELOPMENT TO DRIVE GROWTH 42 FIGURE 8 ANTIBODY SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 43 FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 44 FIGURE 10 NEXT-GENERATION DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45 FIGURE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS 53 FIGURE 12 NEXT-GENERATION DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 13 NEXT-GENERATION DRUG CONJUGATES MARKET: ECOSYSTEM ANALYSIS 59 FIGURE 14 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD) 61 FIGURE 15 INDICATIVE SELLING PRICE, BY REGION, 2025 (USD) 62 FIGURE 16 NEXT-GENERATION DRUG CONJUGATES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64 FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 64 FIGURE 18 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET 73 FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 86 FIGURE 20 KEY BUYING CRITERIA, BY END USER 87 FIGURE 21 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT 177 FIGURE 22 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT 203 FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION) 245 FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 246 FIGURE 25 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 249 FIGURE 26 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY FOOTPRINT 250 FIGURE 27 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 255 FIGURE 28 EV/EBITDA OF KEY VENDORS 258 FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 258 FIGURE 30 NEXT-GENERATION DRUG CONJUGATES MARKET: BRAND COMPARATIVE ANALYSIS 259 FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2025) 265 FIGURE 32 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024) 268 FIGURE 33 NOVARTIS AG: COMPANY SNAPSHOT (2025) 273 FIGURE 34 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 278 FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025) 283 FIGURE 36 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 286 FIGURE 37 RAKUTEN GROUP, INC.: COMPANY SNAPSHOT (2025) 290 FIGURE 38 NOVO NORDISK: COMPANY SNAPSHOT (2025) 293 FIGURE 39 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2025) 295 FIGURE 40 SANOFI: COMPANY SNAPSHOT (2025) 298 FIGURE 41 ARROWHEAD PHARMACEUTICALS: COMPANY SNAPSHOT (2025) 300 FIGURE 42 RESEARCH DESIGN 311 FIGURE 43 NEXT-GENERATION DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES 313 FIGURE 44 NEXT-GENERATION DRUG CONJUGATES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 314 FIGURE 45 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 315 FIGURE 46 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF ALNYLAM PHARMACEUTICALS (2025) 315 FIGURE 47 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 316 FIGURE 48 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 317 FIGURE 49 NEXT-GENERATION DRUG CONJUGATES MARKET CAGR PROJECTIONS 318 FIGURE 50 DATA TRIANGULATION METHODOLOGY 320